| A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma (NCT02383368) | Astellas Pharma Global Development, Inc. | 2015-03-23 |
| A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) (NCT02332668) | Merck Sharp & Dohme LLC | 2015-03-19 |
| Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation (NCT02210065) | M.D. Anderson Cancer Center | 2015-03-03 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source (NCT02167958) | Rafic Farah, MD | 2015-02-11 |
| A Pilot RCT of the PRISM Intervention for AYAs With Cancer (NCT02340884) | Seattle Children's Hospital | 2015-01-30 |
| Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (NCT02106988) | M.D. Anderson Cancer Center | 2015-01-16 |
| Testing a Personalize Medication Log for Patients With Lymphoma (NCT02370446) | Memorial Sloan Kettering Cancer Center | 2015-01-01 |
| A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (NCT02220842) | Hoffmann-La Roche | 2014-12-18 |
| Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies (NCT02305979) | Wake Forest University Health Sciences | 2014-12-01 |
| A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma (NCT02349698) | Southwest Hospital, China | 2014-12-01 |
| A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) (NCT02327078) | Incyte Corporation | 2014-11-26 |
| Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) (NCT02301364) | Memorial Sloan Kettering Cancer Center | 2014-11-20 |
| Blood Samples to Identify Biomarkers of Busulfan (NCT02291965) | Fred Hutchinson Cancer Center | 2014-11-01 |
| Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma (NCT02221492) | Genzyme, a Sanofi Company | 2014-11-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells (NCT02274506) | M.D. Anderson Cancer Center | 2014-10-20 |
| A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (NCT02257567) | Hoffmann-La Roche | 2014-10-15 |
| A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (NCT02130869) | St. Jude Children's Research Hospital | 2014-10-10 |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (NCT02294552) | Ivan S Moiseev | 2014-10-01 |
| Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy (NCT02229682) | Sun Yat-sen University | 2014-10-01 |
| Molecular and Whole-body MR Imaging in Lymphomas (NCT02389101) | Turku University Hospital | 2014-10-01 |
| Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma (NCT02282358) | Memorial Sloan Kettering Cancer Center | 2014-10-01 |
| Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (NCT02323867) | Children's Hospital of Philadelphia | 2014-10-01 |
| Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma (NCT02238873) | Rabin Medical Center | 2014-10-01 |
| ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas (NCT02264613) | Aileron Therapeutics, Inc. | 2014-10-01 |
| Relaxation and Exercise In Lymphoma Patients (NCT02272751) | St George's, University of London | 2014-09-01 |
| Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma (NCT04511351) | Chinese Academy of Medical Sciences | 2014-08-01 |
| FDG-PET/CT Imaging as Early Predictor of DP (NCT02476734) | Abramson Cancer Center at Penn Medicine | 2014-08-01 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (NCT02042950) | M.D. Anderson Cancer Center | 2014-07-14 |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (NCT02559583) | Janssen-Cilag Ltd. | 2014-07-01 |
| Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) (NCT01926665) | M.D. Anderson Cancer Center | 2014-06-17 |
| Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection (NCT02095951) | Children's Hospital of Michigan | 2014-06-01 |
| Improving Patient Education for Lymphoma and Leukemia Inpatients (NCT02642510) | Emory University | 2014-06-01 |
| Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma (NCT01900496) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-06-01 |
| EBUS-TBNA Versus EBUS-TBNB (NCT01467635) | Royal Brompton & Harefield NHS Foundation Trust | 2014-05-01 |
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy (NCT02062632) | Mayo Clinic | 2014-04-14 |
| ACY-1215 for Relapsed/Refractory Lymphoid Malignancies (NCT02091063) | Jennifer Amengual | 2014-04-02 |
| Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children (NCT02129049) | University of Washington | 2014-04-01 |
| AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE) (NCT02595255) | Erasme University Hospital | 2014-04-01 |
| A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors (NCT02145559) | University of Chicago | 2014-04-01 |
| Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) (NCT02038946) | Bristol-Myers Squibb | 2014-03-26 |
| Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB (NCT01953783) | Millennium Pharmaceuticals, Inc. | 2014-03-19 |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma (NCT01902225) | Weiyun Ai | 2014-03-04 |
| Delayed Effects of Treatment in Cancer Survivors (DETECS) (NCT02067637) | University of Colorado, Denver | 2014-03-01 |
| Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy (NCT02056548) | Seoul St. Mary's Hospital | 2014-03-01 |
| Brazilian Network for Lymphoma Registry (NCT02265497) | Claudio Gustavo Stefanoff | 2014-03-01 |
| Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) (NCT01988571) | Wake Forest University Health Sciences | 2014-02-01 |
| Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas (NCT02076451) | Daiichi Sankyo | 2014-02-01 |
| Study of Eribulin in Children With Cancer to Determine Safety (NCT02082626) | University of Oklahoma | 2014-02-01 |
| Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT (NCT03977103) | University Of Perugia | 2014-02-01 |
| Whole Body PET-MRI in Paediatric and Adolescent Lymphoma (NCT02935348) | University College, London | 2014-02-01 |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (NCT01974440) | Janssen Research & Development, LLC | 2014-01-31 |
| Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (NCT01909934) | Takeda | 2014-01-23 |
| A Study of LY2835219 in Japanese Participants With Advanced Cancer (NCT02014129) | Eli Lilly and Company | 2013-12-18 |
| DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (NCT00889408) | Masonic Cancer Center, University of Minnesota | 2013-12-02 |
| Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion (NCT02053545) | Ann & Robert H Lurie Children's Hospital of Chicago | 2013-12-01 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma (NCT01983969) | M.D. Anderson Cancer Center | 2013-11-07 |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (NCT01919619) | M.D. Anderson Cancer Center | 2013-11-04 |
| Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma (NCT01991938) | Verastem, Inc. | 2013-11-01 |
| LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (NCT01986426) | Lytix Biopharma AS | 2013-11-01 |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies (NCT01998035) | Columbia University | 2013-11-01 |
| Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma (NCT03168035) | NanoCarrier Co., Ltd. | 2013-11-01 |
| Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb (NCT02012088) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2013-10-11 |
| Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy (NCT01921998) | The Christie NHS Foundation Trust | 2013-10-01 |
| Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection -The European Perspective (NCT02287012) | Pr Mohamad MOHTY | 2013-10-01 |
| Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (NCT01956695) | Institut Curie | 2013-09-18 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies (NCT01947140) | Jennifer Amengual | 2013-09-09 |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma (NCT01949883) | Constellation Pharmaceuticals | 2013-09-05 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma (NCT01855750) | Janssen Research & Development, LLC | 2013-09-03 |
| Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients (NCT02012465) | Washington University School of Medicine | 2013-09-01 |
| PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy (NCT02805218) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2013-09-01 |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain (NCT01846429) | H. Lee Moffitt Cancer Center and Research Institute | 2013-09-01 |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis (NCT02065154) | University of Alabama at Birmingham | 2013-08-27 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma (NCT01962532) | Janssen Research & Development, LLC | 2013-08-21 |
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) (NCT01889069) | Hoffmann-La Roche | 2013-07-31 |
| Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas (NCT01898078) | Millennium Pharmaceuticals, Inc. | 2013-07-16 |
| A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas (NCT01877382) | Daiichi Sankyo | 2013-07-11 |
| Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma (NCT01908413) | Curis, Inc. | 2013-07-01 |
| Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas (NCT02049580) | Istituto Clinico Humanitas | 2013-07-01 |
| Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (NCT01610999) | Tufts Medical Center | 2013-07-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative (NCT01916135) | Memorial Sloan Kettering Cancer Center | 2013-07-01 |
| Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib (NCT01844583) | Millennium Pharmaceuticals, Inc. | 2013-06-25 |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (NCT01793233) | Children's Oncology Group | 2013-06-17 |
| PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (NCT01855698) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-06-01 |
| Acupuncture for Chemotherapy-induced Peripheral Neuropathy (NCT01892852) | Pusan National University Hospital | 2013-06-01 |
| Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma (NCT06795113) | Ruijin Hospital | 2013-06-01 |
| Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia (NCT01928017) | University of Bergen | 2013-06-01 |
| Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma (NCT01390584) | ECOG-ACRIN Cancer Research Group | 2013-05-24 |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies (NCT01871675) | SCRI Development Innovations, LLC | 2013-05-01 |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (NCT01729104) | M.D. Anderson Cancer Center | 2013-04-25 |
| A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma (NCT01779791) | Janssen Research & Development, LLC | 2013-04-17 |
| Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy (NCT01841814) | Centre Hospitalier Universitaire, Amiens | 2013-04-01 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (NCT01829971) | Mirna Therapeutics, Inc. | 2013-04-01 |
| Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly (NCT01671813) | H. Lee Moffitt Cancer Center and Research Institute | 2013-03-01 |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant (NCT01744223) | Bellicum Pharmaceuticals | 2013-03-01 |
| Cardiac Fibrosis by CMR in Patients With Cancer (NCT01906437) | Massachusetts General Hospital | 2013-03-01 |